COPENHAGEN, October 15, 2025 – Novo Nordisk (NVO) signed a 2.1 billion licensing deal with Omeros (OMER) for rare disease drug zaltenibart, sending Omeros shares soaring.
The acquisition expands Novo’s portfolio beyond diabetes into rare diseases, while providing Omeros crucial funding for its clinical programs.
- Omeros receives 340 million upfront and near-term milestone payments
- Deal targets MASP-3 inhibitor for rare complement-mediated diseases
- Omeros stock surges on billion-dollar partnership announcement
Market Reaction & Context
Omeros stock soared following the announcement, reflecting investor enthusiasm for the transformative deal 4. The agreement provides immediate liquidity for the Seattle-based biotech company, which has been developing zaltenibart (OMS906) as a treatment for rare complement-mediated diseases.
Novo Nordisk’s move into rare diseases aligns with the Danish drugmaker’s strategy to diversify beyond its dominant diabetes franchise. The company has been leveraging strong cash flows from blockbuster GLP-1 drugs like Ozempic and Wegovy to fund acquisitions in specialized therapeutic areas.
Deal Structure & Financial Terms
Under the definitive asset purchase and license agreement, Omeros will receive 340 million in upfront payments and near-term milestones 5. The total potential value reaches 2.1 billion when including all development, regulatory and commercial milestone payments.
Zaltenibart is a clinical-stage MASP-3 inhibitor designed to treat complement-mediated diseases, a group of rare conditions caused by overactivation of the immune system’s complement pathway 2. The drug represents a novel approach to treating these debilitating conditions that currently have limited treatment options.
Strategic Rationale
The acquisition gives Novo Nordisk access to a promising rare disease asset while allowing the company to leverage its global commercial infrastructure. Rare disease drugs typically command premium pricing and face less competitive pressure than mass-market treatments.
For Omeros, the partnership provides validation of its complement inhibition platform and sufficient funding to advance other pipeline programs. The company has struggled with funding challenges in recent years, making this deal particularly significant for its long-term viability.
Development Timeline
Zaltenibart is currently in clinical development, with Novo Nordisk expected to take over regulatory responsibilities and advance the program through pivotal trials. The companies did not disclose specific timelines for regulatory submissions or potential approvals.
Complement-mediated diseases affect thousands of patients worldwide, creating a substantial market opportunity for effective treatments. The MASP-3 pathway represents a relatively unexplored target in complement inhibition, potentially offering advantages over existing therapies.
Not investment advice. For informational purposes only.
References
1“Novo Nordisk signs up to 2.1 billion licensing deal with Omeros in …”. Yahoo Finance. Retrieved October 15, 2025.
2“Novo Nordisk and Omeros announce asset purchase and license agreement”. Globe Newswire. Retrieved October 15, 2025.
3“Novo Agrees Asset and License Deal With Omeros for Zaltenibart”. Bloomberg Law. Retrieved October 15, 2025.
4“Omeros stock soars after 2.1 billion deal with Novo Nordisk”. Investing.com. Retrieved October 15, 2025.
5“Novo Nordisk Inks Billion-Dollar Deal for Omeros MASP-3 Inhibitor”. MarketScreener. Retrieved October 15, 2025.